Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns

Since direct oral anticoagulants (DOACs) have been introduced for treatment and prevention of thromboembolic diseases, patients on vitamin K antagonists (VKA) have to decide whether to remain on VKA or switch to DOAC. The goal of this study was to evaluate treatment satisfaction, preferences, and concerns among those who already have switched from VKA to DOAC.

[1]  Z. Babar,et al.  A systematic review of patient‐reported outcomes associated with the use of direct‐acting oral anticoagulants , 2019, British journal of clinical pharmacology.

[2]  Hugh Calkins,et al.  2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2019, Heart rhythm.

[3]  A. Camm,et al.  The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. , 2018, European heart journal.

[4]  M. Cushman,et al.  Anticoagulant Preferences and Concerns among Venous Thromboembolism Patients , 2018, Thrombosis and Haemostasis.

[5]  C. Sindet-Pedersen,et al.  Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark , 2017, European heart journal.

[6]  H. Buller,et al.  Preference for direct oral anticoagulants in patients treated with vitamin K antagonists for venous thromboembolism. , 2017, The Netherlands journal of medicine.

[7]  Eureka week,et al.  Dutch grading system , 2016 .

[8]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[9]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.

[10]  P. Austin,et al.  Socioeconomic status and risk of hemorrhage during warfarin therapy for atrial fibrillation: A population-based study. , 2015, American heart journal.

[11]  G. Breithardt,et al.  Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). , 2014, Journal of the American College of Cardiology.

[12]  S. Yusuf,et al.  The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). , 2014, Journal of the American College of Cardiology.

[13]  Brooks C. Holtom,et al.  Survey response rate levels and trends in organizational research , 2008 .

[14]  C. McKevitt,et al.  Socioeconomic status and stroke , 2006, The Lancet Neurology.

[15]  D. Singer,et al.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. , 2001, JAMA.

[16]  T. Astrup.  [New aspects in blood coagulation and fibrinolysis and their relations to coronary thrombosis and coronary sclerosis]. , 1958, Wiener Zeitschrift fur innere Medizin und ihre Grenzgebiete.